Investigational drug · Phase 2
REGN5093
Also called: davutamig
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "REGN5093"
First trial start
2020
Jan 7, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN5093", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN5093" as an intervention, largest first.
- A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04077099 · 95 participants · Start Jan 7, 2020 · Primary completion Jul 6, 2027
Drug: REGN5093 · For: NSCLC
Sites: Orange, California; Washington D.C., District of Columbia; Tampa, Florida · 29 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04982224 · 30 participants · Start Nov 9, 2021 · Primary completion Oct 15, 2025
Drug: REGN5093-M114; Cemiplimab · For: Advanced NSCLC
Sites: Orange, California; Denver, Colorado; Baltimore, Maryland · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation.
Li Y, Li Y, Huang R, et al. · Front Immunol 2026
- Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions.
Wang K, Hsu R · Antibodies (Basel) 2024
- REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?
Dardare J, Witz A, Harlé A · Transl Lung Cancer Res 2024
- Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET.
Evers A, Krah S, Demir D, et al. · MAbs 2024
- Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
Oh SY, Lee YW, Lee EJ, et al. · Clin Cancer Res 2023
Also in development for NSCLC
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.